共 122 条
- [1] Pollock PA(2015)In 2124, half of all men can count on developing prostate cancer Curr Oncol 22 10-12
- [2] Ludgate A(2019)(68)Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA < 0.5 ng/ml. Efficacy and impact on treatment strategy Eur J Nucl Med Mol Imaging 46 11-19
- [3] Wassersug RJ(2019)(68)Ga-PSMA PET/CT for monitoring response to (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer Eur J Nucl Med Mol Imaging 46 1054-1062
- [4] Farolfi A(2019)(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging? Wien Med Wochenschr 169 3-11
- [5] Ceci F(2019)Re: [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Eur Urol 75 536-537
- [6] Castellucci P(2019)(177)Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney J Nucl Med 12 2677-2685
- [7] Graziani T(2012)Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC Curr Top Med Chem 35 839-849
- [8] Siepe G(2008)Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides Nucl Med Biol 66 497-505
- [9] Lambertini A(2008)Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors Appl Radiat Isot 2012 320198-1287
- [10] Schiavina R(2012)Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience J Oncol 61 1279-34